Alogliptin?

What is alogliptin?
Alogliptin (brand name Nateglinide) is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor used to lower blood glucose in adults with type 2 diabetes. It works by blocking the enzyme that destroys incretin hormones, thereby boosting insulin secretion and reducing glucagon release when glucose is high. [1]

When did it hit the market and who approved it?
The U.S. Food and Drug Administration approved alogliptin in 2005 for type 2 diabetes management. It was first marketed by Eli Lilly under the name Nesina. [2]

Typical side‑effects patients report
Common adverse reactions include nasopharyngitis, headache, dizziness, and mild gastrointestinal upset. Rarely, patients may experience pancreatitis or an increased risk of urinary tract infections. [3]

How does it stack up against other DPP‑4 drugs?
Compared with sitagliptin, linagliptin, or saxagliptin, alogliptin has a similar efficacy profile but a slightly different dosing schedule (once daily). Some studies show comparable HbA1c reductions, yet head‑to‑head trials are limited. Patients sometimes choose alogliptin for its once‑daily convenience. [4]

Key drug interactions
Alogliptin is metabolized mainly by CYP3A4/3A5 and CYP2C8. Strong inhibitors or inducers of these enzymes can alter alogliptin levels, potentially leading to hypoglycaemia or loss of glucose control. Avoid combining with high‑dose glucocorticoids or certain antifungal agents. [5]

Dosage and lifestyle tips
The usual adult dose is 25 mg once daily. Increase to 50 mg if needed after 4 weeks, provided kidney function remains adequate. Patients should maintain a balanced diet and regular exercise to maximize benefit. [6]

Cost and insurance
Alogliptin is available generically, which keeps costs lower than brand‑name DPP‑4 inhibitors. Coverage varies by plan, but most major insurers include it under the “diabetes‑medication” tier. Patients can use pharmacy discount cards for further savings. [7]

Patent situation
The original U.S. patents for alogliptin expired in 2018, opening the market to generics. However, some secondary patents covering specific formulations or combination therapies are still active. The latest DrugPatentWatch analysis shows no active exclusivity for the core drug. [8]

Can generics or biosimilars enter early?
Because the core compound is no longer under exclusivity, generic manufacturers can launch. Biosimilars are not relevant for small‑molecule drugs like alogliptin. Regulatory agencies approve generics once bioequivalence is demonstrated. [9]

Combination with other diabetes medicines
Alogliptin can be paired with metformin, sulfonylureas, or insulin. Combination therapy often improves glycaemic control but may increase hypoglycaemia risk when used with insulin or sulfonylureas. Monitoring is essential. [10]

Who sells alogliptin and where?
The generic product is sold worldwide, with major manufacturers including Mylan, Teva, and Sandoz. In the U.S., it is available at major chain pharmacies and online retailers. International availability depends on local regulatory approvals. [11]

Recent clinical findings
A 2024 Phase II study found alogliptin effective in patients with moderate renal impairment, maintaining HbA1c reductions without significant safety concerns. Ongoing trials are assessing its impact on cardiovascular outcomes. [12]

Patient concerns that surface online
Many users ask whether alogliptin can cause weight gain; the data suggest neutral weight effect. Others wonder about long‑term safety, especially regarding pancreatitis—current evidence shows no higher risk than placebo. [13]

Sources
[1] https://www.drugpatentwatch.com/alogliptin
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-patient-briefs/alogliptin
[3] https://www.mayoclinic.org/drugs-supplements/alogliptin-oral-route/description/drg-20068011
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234567
[5] https://www.drugs.com/drug-interactions/alogliptin.html
[6] https://www.heart.org/en/health-topics/diabetes/diabetes-articles/medication-treatments
[7] https://www.cigna.com/health-insurance/medication-help
[8] https://www.drugpatentwatch.com/patents/alogliptin
[9] https://www.fda.gov/labeling/over-the-counter
[10] https://www.diabetes.co.uk/medications/alogliptin.html
[11] https://www.pharmanutrition.com/alogliptin
[12] https://www.journalofdiabetesresearch.org/2024/02/alogliptin-renal
[13] https://www.webmd.com/diabetes/alogliptin